Sudden Blast Crisis After Excellent Initial Response in Chronic Myeloid Leukemia.
bcr-abl
blast crisis
chronic myeloid leukemia (cml)
imatinib
rt- qpcr
tyrosine kinase receptor inhibitors
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
accepted:
28
09
2021
entrez:
3
11
2021
pubmed:
4
11
2021
medline:
4
11
2021
Statut:
epublish
Résumé
Sudden blast crisis is an uncommon phenomenon in chronic myeloid leukemia (CML) patients who are being treated with tyrosine kinase inhibitors (TKIs). Despite well-defined guidelines to treat and monitor the disease, it is difficult to predict the occurrence of a sudden blast crisis. Research directed towards improving guidelines in choosing the appropriate TKIs and better monitoring protocols could help prevent such unfortunate outcomes. We present a case of a 46-year-old man diagnosed with CML who responded well to imatinib as evidenced by a downtrend in quantitative BCR-ABL mutation to less than 1. He quickly transformed into a blast crisis phase after five months of therapy with imatinib regardless of achieving an excellent initial optimal response. In conclusion, it is possible to transform into a blast phase despite achieving an initial optimal response. Therefore, attention should be focused on the selection of proper tyrosine kinase inhibitors and careful monitoring to allow the early detection of sudden blast crisis.
Identifiants
pubmed: 34729261
doi: 10.7759/cureus.18368
pmc: PMC8555935
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e18368Informations de copyright
Copyright © 2021, Vijaya Prakash et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Oncol Pract. 2018 Jun;14(6):e324-e334
pubmed: 29799768
Leukemia. 2020 Apr;34(4):966-984
pubmed: 32127639
Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51
pubmed: 28881915
Int J Hematol. 2018 Apr;107(4):495-497
pubmed: 29032513
Cancer. 2006 Sep 1;107(5):1008-13
pubmed: 16878324
Ann Hematol. 2015 Dec;94(12):2015-24
pubmed: 26385387
J Med Case Rep. 2020 Nov 27;14(1):231
pubmed: 33243265
Hematol Oncol Clin North Am. 2009 Aug;23(4):655-74
pubmed: 19577163
Blood Cancer J. 2016 Aug 26;6(8):e461
pubmed: 27564459
PLoS One. 2019 Mar 5;14(3):e0207170
pubmed: 30835732
Drugs. 2014 May;74(7):793-806
pubmed: 24807266
N Engl J Med. 2010 Jun 17;362(24):2260-70
pubmed: 20525995
Cancer. 2003 Jul 1;98(1):81-5
pubmed: 12833459
Int J Hematol. 2016 Mar;103(3):348-53
pubmed: 26662559
J Clin Oncol. 2012 Oct 1;30(28):3486-92
pubmed: 22949154
Cancer Cell. 2020 Apr 13;37(4):530-542
pubmed: 32289275
Cancer Sci. 2018 Jan;109(1):182-192
pubmed: 29058817
Blood. 2006 Jan 15;107(2):480-2
pubmed: 16195326
Cancer Manag Res. 2021 Feb 10;13:1233-1243
pubmed: 33603469
J Clin Oncol. 2010 Jan 20;28(3):392-7
pubmed: 20008621
Am J Hematol. 2016 Feb;91(2):252-65
pubmed: 26799612
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):168-176
pubmed: 30504306